Psychiatry Investig Search


Psychiatry Investig > Volume 17(11); 2020 > Article
Park, Kim, and Kim: Relationship of Change in Plasma Clozapine/N-desmethylclozapine Ratio with Cognitive Performance in Patients with Schizophrenia



The clozapine/N-desmethylclozapine (NDMC) ratio is proposed to be used as a predictor of cognitive performance in clozapine-treated patients, as its principal metabolite, NDMC, has an opposite action with clozapine on the cholinergic system. The aim of this study is to determine whether clozapine has influence on cognitive performance in accordance with changes in the clozapine/NDMC in patients with schizophrenia.


The data of fifteen patients with schizophrenia, who had initial and follow-up assessments after starting clozapine treatment, were retrospectively collected. The assessments included clinical scale, cognitive battery, and pharmacological data including plasma concentrations of clozapine and NDMC. The data were analyzed with Pearson correlation and stepwise multiple regression analyses.


ΔAttention/vigilance, Δsocial cognition, and Δcomposite score had a significant correlation with Δclozapine/NDMC ratio, while ΔWorking memory had correlation with Δclozapine concentration and ΔNDMC concentration, and Δsocial cognition had association with Δclozapine concentration. Multiple regression analysis showed that Δattention/vigilance had negative association with Δclozapine/NDMC ratio, Δworking memory had negative relation with Δclozapine concentration, and that Δsocial cognition had negative association with Δclozapine concentration.


This finding implicates that lowering the clozapine/NDMC ratio could enhance cognition in patients with schizophrenia treated with clozapine.


Cognitive and negative symptoms of schizophrenia tend to be chronic and are associated with poor functional outcomes, compared to positive symptoms of schizophrenia [1]. Cognitive impairments in schizophrenia have been identified in a wide range of domains, including verbal memory, working memory, motor speed, attention, executive function, and verbal fluency [2]. These impairments have been shown to affect functioning in everyday life, including interpersonal relationships and work skills [3,4]. Although more than 50 clinical trials have been conducted in patients with schizophrenia, no medications have yet been approved by the FDA to treat cognitive impairments in patients with schizophrenia [5,6].
Clozapine is effective for treatment-resistant schizophrenia [7]. Notably, clozapine is more efficacious for positive and negative symptoms and for improving patients’ quality of life in treatment-resistant schizophrenia, compared to first-generation antipsychotics [8]. Nevertheless, the effect of clozapine on cognitive symptoms remains controversial. In the past, clozapine was presumed to produce pro-cognitive effects through its multireceptor action, which increased hippocampal acetylcholine efflux [9,10], however, clinical trials regarding the cognitive effects of clozapine in patients with schizophrenia have shown mixed results, ranging from deleterious [11] to beneficial [6,12].
The conflicting results regarding the effects of clozapine on cognition are presumably related in part to the differing actions of clozapine and its major active metabolite, N-desmethylclozapine (NDMC), on the cholinergic system [13,14]. Clozapine is an antagonist of muscarinic M1, M3, and M5 receptors; thus, it has anti-cholinergic activity [15,16], which may worsen cognition. In contrast, NDMC is a potent partial agonist of those same receptors and is predicted to enhance cognition [17,18]. Furthermore, clozapine metabolism significantly varies among patients, resulting in NDMC plasma levels ranging from 20% to 150% of clozapine concentrations [19]. Thus, the anticholinergic burden and its consequent effects on cognitive function are likely to be more affected by the clozapine/NDMC ratio than by the clozapine dose or either concentration alone [20].
For this reason, previous studies have examined the association between cognitive performance and the clozapine/NDMC ratio in patients treated with clozapine. For example, negative correlations have been reported between the clozapine/NDMC ratio and some cognitive domains, including working memory, attention, and executive functioning [20-23]. However, all of the studies mentioned above were cross-sectional in design; thus, the impact of change in the clozapine/NDMC ratio on cognitive performance remains largely unknown.
To determine whether clozapine influenced improvement in cognitive performance in accordance with a change in clozapine/NDMC ratio (Δclozapine/NDMC ratio) in patients with schizophrenia, previous longitudinal study examined patients with treatment-resistant schizophrenia for whom data of two or more standardized cognitive assessments and clozapine/NDMC ratio measurements were available within 12-week study period [24]. However, that study had several limitations, including its analysis of patients with unknown clozapine treatment duration, use of simplified versions of clinical and cognitive assessments, and analysis of composite score alone (because of its limited sample size). Hence, we designed this study to address these limitations.
This study was performed to determine the association between improvement in cognitive performance and Δclozapine/NDMC ratio in patients with schizophrenia who started and continued clozapine treatment for more than 2 months. We hypothesized that the Δclozapine/NDMC ratio would be negatively associated with improvement in cognitive function, and we designed the study to determine which cognitive domains were most strongly associated with the Δclozapine/NDMC ratio.


This study was approved by the Institutional Review Board of Seoul National University Bundang Hospital, Gyeonggi-do, Korea and was conducted in accordance with the Helsinki Declaration of 1975, as revised in 2008 (B-1910-570-103).

Data acquisition

Routine clinical data were retrospectively collected from patients who attended Seoul National University Bundang Hospital between January 2016 and September 2019. Patients were included if they 1) were diagnosed with schizophrenia or schizoaffective disorder, based on ICD-10 criteria; 2) were older than 19 years; and 3) started clozapine treatment and completed initial and follow-up assessments (e.g., pharmacological, clinical, and cognitive assessments). Initial assessments were defined as those performed within one month (30 days) of clozapine treatment initiation; follow-up assessments were defined as those performed more than 2 months (60 days) after initiation of clozapine (Figure 1).

Demographic data and pharmacological assessments

Age, sex, and years of education at the initial assessment were collected as demographic data. Participants underwent blood sampling as part of routine patient monitoring to detect the plasma levels of clozapine and NDMC, which were obtained through liquid chromatography-tandem mass spectrometry [25]. Other pharmacological data, such as clozapine dose and other medications (e.g., antipsychotics, antidepressants, mood stabilizers, benzodiazepines, anticholinergics, and beta blockers), were obtained from patients’ medical records.

Clinical and cognitive assessments

Clinical symptoms were assessed using the Positive and Negative Syndrome Scale (PANSS) [26]. Cognition was assessed using the Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Consensus Cognitive Battery (MCCB), which was developed to assess cognitive treatment effects in clinical trials involving patients with schizophrenia; it is considered the Food and Drug Administration (FDA) gold standard outcome measure for that purpose [27,28]. The MCCB includes 10 tests that assess the following seven cognitive domains:
1) Processing speed [Trail Making Test, part A (TMT), symbol coding task of the Brief Assessment of Cognition in Schizophrenia (BACS), and category fluency (Fluency)]
2) Attention/Vigilance [Continuous Performance Test-Identical Pairs (CPT-IP)]
3) Working memory [Spatial Span test (SS) and Letter-Number Span test (LNS) of the Wechsler Memory Scale-3rd Ed.]
4) Verbal learning [Hopkin’s Verbal Learning Test-Revised (HVLT-R)]
5) Visual learning [Brief Visuospatial Memory Test-Revised (BVMT-R)]
6) Reasoning and problem solving [Mazes test (Mazes) of the Neuropsychological Assessment Battery]
7) Social cognition [Managing Emotions test (ME) of the Mayer-Salovey-Caruso Emotional Intelligence Test]
T-scores for each cognitive domain, standardized and corrected for age and sex, were used as individual outcome measures [29]. The overall composite score was the standardized total of scores for the seven domains.

Statistical analysis

All statistical analyses (*p<0.05 and **p<0.01) were performed using IBM SPSS Statistics, version 23.0 (IBM Corp., Armonk, NY, USA). To compare initial and follow-up assessments of pharmacological, clinical, and cognitive variables, paired t-tests or Wilcoxon signed-rank tests were used, in accordance with homogeneity and normality. Four patients underwent initial pharmacologic assessments before initiation of clozapine treatment, resulting in initial clozapine and NDMC concentration values of 0; the initial clozapine/NDMC ratios of these four patients were defined as 0. Pearson correlation analyses were used to explore relationships between relative delta values that were calculated as changes proportional to the initial value [Δ=(assessment at follow-up-assessment at baseline)/(assessment at baseline)×100] for each cognitive performance domain (T-scores), as well as for demographic, clinical, and pharmacological variables [Δclozapine/NDMC ratio =(clozapine/NDMC ratio at follow-up-clozapine/NDMC ratio at baseline)/(clozapine/NDMC ratio at baseline)×100]. Multiple regression analyses were performed using the delta values of each cognitive score as dependent variables (response, y); demographic (years of education), clinical (ΔPANSS total and subscale scores), and pharmacological variables (Δclozapine concentration, ΔNDMC concentration, and Δclozapine/NDMC ratio) were used as independent variables (predictors, x). Each model was built using a stepwise forward-backward variableselection method; the independent variables were entered or removed from the model based on the default p-values, 0.05 and 0.10, respectively.


Fifteen patients met the inclusion criteria, including the completion of initial and follow-up assessments. After the initiation of clozapine treatment, initial and follow-up pharmacological assessments were made on days 11.08±18.77 [mean± standard deviation (SD)] and 106.33±38.37, respectively; clinical and cognitive assessments were made on days 3.31±9.59 and 104.33±33.82, respectively. The demographic, pharmacological, and clinical characteristics of the 15 patients who met the inclusion criteria are provided in Table 1. The mean patient age was 34.13±13.31 years, the proportion of women was 66.7%, and the mean duration of education was 13.47±2.75 years. The mean clozapine doses were 135.00±122.32 mg/d at the initial assessment and 199.17±86.42 mg/d at the follow-up assessment. The total PANSS scores were 77.92±19.70 at the initial assessment and 75.27±18.27 at the follow-up assessment. Compared with the initial assessment, the NDMC concentration was significantly elevated at the follow-up assessment (z=-1.988, p=0.047); however, the clozapine dosage (t=-1.850, df=14, p=0.086), clozapine concentration (t=-0.961, df=14, p=0.353), clozapine/NDMC ratio (t=-0.180, df=14, p=0.860), PANSS total scores (z=-0.035, p=0.972), and PANSS subscale scores (positive: t=1.156, df=14, p=0.270; negative: t=0.047, df=14, p=0.963; general: z=-0.236, p=0.814) did not significantly change.
Cognitive outcomes are presented as T-scores in Table 2. Processing speed demonstrated a significant elevation in Tscore at the follow-up assessment, compared to the initial assessment (t=-2.229, df=14, p=0.043); however, no significant individual changes were observed in its three corresponding tests [TMT (t=-1.605, df=14, p=0.131), BACS (t=-1.493, df=14, p=0.158), and Fluency (t=-1.405, df=14, p=0.182)]. Attention/ vigilance and its corresponding test, CPT-IP, showed a significant elevation in T-score at the follow-up assessment, compared to the initial assessment (t=-3.031, df=14, p=0.009). Although there was no significant change in the working memory domain (t=-1.519, df=14, p=0.151), there was a significant elevation in T-score in the letter-number span (t=-2.359, df=14, p=0.033) at the follow-up assessment, compared with the initial assessment; notably, there was no change in the spatial span (t=-0.922, df=14, p=0.372). The overall composite score also exhibited a significant enhancement at the follow-up assessment, compared to the initial assessment (t=-2.275, df=14, p=0.040). The remaining domains [i.e., verbal learning (t=0.372, df=14, p=0.715), visual learning (t=-0.801, df=14, p=0.437), reasoning and problem solving (t=-0.994, df=14, p=0.337), and social cognition (t=0.294, df=14, p=0.773)] exhibited no changes between initial and follow-up assessments.
Correlations between the Δclozapine/NDMC ratio and delta values of each cognitive domain are presented in Figure 2. The values of 4 patients that had initial assessments before clozapine initiation were not included in the analysis. ΔAttention/vigilance (r=-0.678, p=0.022), Δsocial cognition (r=-0.646, p=0.032), and Δcomposite score (r=-0.610, p=0.046) were significantly correlated with the Δclozapine/NDMC ratio; whereas other domains [e.g., Δprocessing speed (r=-0.366, p=0.268), Δworking memory (r=-0.561, p=0.072), Δverbal learning (r=-0.370, p=0.263), Δvisual learning (r=-0.489, p=0.127), and Δreasoning and problem solving (r=-0.412, p=0.208)], showed no correlations (Figure 2). ΔWorking memory and Δsocial cognition were significantly correlated with other variables: ΔWorking memory was correlated with the Δclozapine concentration (r=-0.689, p=0.019) and the ΔNDMC concentration (r=-0.689, p=0.019), while Δsocial cognition was association with the Δclozapine concentration (r=-0.762, p=0.006).
The results of multiple regression analysis, which examined delta values of cognitive domains as dependent variables, are summarized in Table 3. The values of 4 patients that had initial assessments before clozapine initiation were not included in the analysis. ΔAttention/vigilance was negatively associated with the Δclozapine/NDMC ratio (B=-1.083, SE B=0.418, β=-0.676, p=0.032), whereas other Δcognitive domain scores displayed no association with this ratio. ΔWorking memory and Δsocial cognition were negatively associated with the Δclozapine concentration (Δworking memory: B=-0.384, SE B=0.141, β=-0.695, p=0.026; Δsocial cognition: B=-0.416, SE B=0.081, β=-0.877, p=0.001). ΔProcessing speed, Δverbal learning, Δvisual learning, Δreasoning and problem solving, and Δcomposite score in the cognitive domains exhibited no significant associations with any independent variables.


To the best of our knowledge, this is the first study to examine the relationship between the Δclozapine/NDMC ratio and cognitive performance in patients with schizophrenia at the initiation of clozapine treatment. The Δclozapine/NDMC ratio was strongly and negatively associated with improvements in attention/vigilance performance; these findings suggested that NDMC (a potent partial agonist of muscarinic M1, M3, and M5 receptors) can contribute to cognitive enhancement in patients with schizophrenia who receive clozapine treatment. Notably, this association was independent of symptom severity.
Our findings extend those of previous cross-sectional studies regarding the relationship between this ratio and cognitive performance in patients with schizophrenia who receive clozapine treatment, which have reported that lower clozapine/NDMC ratios were associated with higher cognitive performance [14,20-23]. Because of the differing actions of clozapine and NDMC on the cholinergic system, the clozapine/NDMC concentration ratio (rather than clozapine dose or either concentration alone) has been proposed as a predictor of cognitive performance in patients undergoing clozapine treatment [20]. However, the cross-sectional design of the prior study only allowed examination of correlations between the clozapine/NDMC ratio and cognitive performance; neither a causal relationship between the change in cognitive performance and the clozapine/NDMC ratio nor the impact of changing that ratio on cognitive performance could be demonstrated. Analysis of pharmacological and cognitive assessments at two time points enabled examination of the relationship between the Δclozapine/NDMC ratio and cognitive performance.
To our knowledge, only one previous study used a longitudinal approach to assess the association between the clozapine/NDMC ratio and cognition [24]. That study, which was notable for exploring changes in cognition as a function of changes in pharmacologic factors, revealed a negative correlation between the clozapine/NDMC ratio and cognition. However, that study assessed patients with unknown duration of clozapine treatment, used simplified versions of clinical and cognitive assessments (i.e., the positive sub-score of the Clinical Global Impression for Schizophrenia and the BACS), did not analyze the scores of subtests of the BACS due to its limited sample size, and measured changes in pharmacological and cognitive variables directly instead of changes proportional to the initial value; thus, it was difficult to determine whether the analysis was appropriately powered to evaluate this association [24].
Our study analyzed the data of patients with schizophrenia who were starting clozapine treatment and who had their initial assessment within one month from the initiation of clozapine treatment and a follow-up assessment at more than 2 months after initiation of clozapine. Although a cross-sectional study should utilize a time point that represents a stable status for measurement of pharmacologic and cognitive variables, we presumed that analysis of patients who were starting clozapine treatment (rather than patients with long histories of clozapine treatment) would highlight the effects of the Δclozapine/NDMC ratio on cognitive performance. Furthermore, for precise assessment of clinical and cognitive statuses, we used a validated instrument and its cognitive sub-domains, along with a delta value proportional to its initial value. MCCB, a cognitive battery comprising assessments of seven cognitive domains that was used in the present study, is considered the FDA gold standard outcome measure of cognitive treatment effects in clinical trials involving patients with schizophrenia [27,28], the PANSS is a frequently used scale with three subscales that separately assess positive, negative, and general symptoms [26].
The Δclozapine/NDMC ratio had a significant impact on attention/vigilance performance. Lower clozapine/NDMC ratios are associated with greater cholinergic agonism, which mediates cognitive functioning and influences the performance of tasks that heavily depend on complex attentional processes by modulation of attention and encoding memory [21,30]. This association was examined as early as within 2-4 months after initiation of clozapine treatment; it was independent of changes in the severities of positive, negative, general, and total symptoms. Although Δsocial cognition and Δcomposite score were correlated with the Δclozapine/NDMC ratio, these associations did not persist during multiple regression analysis. Identification of influencing factors and mechanisms of changes in other cognitive domains require further analyses.
Attention/vigilance, processing speed, aspects of the working memory domain, and the overall composite score showed elevated T-scores at the follow-up assessment, compared to the initial assessment. Notably, the stepwise multiple regression model revealed that Δattention/vigilance had causal relations with the Δclozapine/NDMC ratio, and that Δworking memory and Δsocial cognition displayed causal relations with the Δclozapine concentration, whereas other Δcognitive domains did not exhibit significant associations with any independent variables. Most other studies either reported no significant associations between clozapine concentration and cognition [20,22,23], or have not reported the results of association analysis with clozapine concentration [21]; one study reported a significant correlation between the Δclozapine concentration and the ΔBACS composite score [24]. Consistent with the findings of a previous publication [24], our study revealed that Δworking memory and Δsocial cognition were causally related to the Δclozapine concentration. Most studies mentioned previously were cross-sectional in nature, whereas the study that reported a significant correlation between the Δclozapine concentration and Δcognitive performance was designed as a longitudinal study. This suggests that the differences among studies in terms of the correlation with clozapine concentration might be due to different study designs; the longitudinal study examined delta values, whereas the cross-sectional studies used values from a single time point.
Our study assessed the impacts of changes in the clozapine/NDMC ratio on cognitive performance; however, the change in that ratio was not controlled by the researchers, but occurred naturally depending on the rate at which each patient metabolized clozapine [31]. This study confirmed the influence of changes in the clozapine/NDMC ratio on cognitive performance, which suggested that routine monitoring of the clozapine/NDMC ratio is crucial for prediction of changes in cognition and evaluation of underlying mechanisms; these data could be used to adjust the clozapine dose to control the ratio. The results of this study imply that artificial reduction of the ratio by manipulation of factors that affect the pharmacokinetics of clozapine might improve cognitive performance in patients with schizophrenia. Targets for manipulation of clozapine pharmacokinetics include hepatic clearance (influenced by polymorphism of CYP1A2 and other related enzymes) [32,33], presystemic metabolism in the gut [34], renal clearance [35], and smoking [36,37] or caffeine intake [38] statuses. Although future controlled studies with larger sample sizes are required to confirm these results, our study supports recent efforts to target muscarinic receptor neurotransmission and develop an agent that inhibits the metabolism of NDMC alone, thereby enhancing cognition without worsening psychotic symptoms.
When interpreting the results of this study, some limitations should be considered. First, this study used retrospectively collected routine clinical data. Although assessments were routinely performed when patient started clozapine treatment, the timing was not strictly controlled; therefore, few eligible patients satisfied the inclusion criteria. Despite the small sample size, the clozapine/NDMC ratio exhibited a significant association with improvement in attention/vigilance in patients with schizophrenia who were starting clozapine treatment, encouraging us to continue with a well-designed prospective study that could better define the impact of the clozapine/NDMC ratio on improvement of cognitive function in patients with schizophrenia. Second, repeated cognitive assessments might have led to a learning effect that could have influenced the results of follow-up cognitive assessments. Nevertheless, the testretest reliability of the MCCB is considered excellent, and the learning effects are confirmed to be small [28,29]. Third, there is a possibility that the improvements of the cognition might be related to the alleviated psychotic symptoms though we put the PANSS score into the statistical analysis as a covariate. Nevertheless, it is unlikely to be the case since there was no significant change in the PANSS score during the study duration. Finally, although there was little or no change in concomitant medications between the initial and follow-up assessments, most patients were taking concomitant medications other than clozapine, which could have had influenced the cholinergic system.
In conclusion, the current findings suggested that clozapine treatment was associated with improvement in cognitive performance, especially in the attention/vigilance domain, in accordance with changes in the clozapine/NDMC ratio in patients with schizophrenia who were starting clozapine treatment. These findings suggested that reduction of the clozapine/NDMC ratio, which would target muscarinic receptor neurotransmission, could enhance cognition in patients with schizophrenia who received clozapine treatment. Our finding also suggested that working memory and social cognition improved in accordance with changes in the clozapine concentration. Future controlled longitudinal studies with larger sample sizes are required to confirm the effects of changes in the clozapine/NDMC ratio or clozapine concentration on cognitive performance.


This work was supported by Research Resettlement Fund for the new faculty of Seoul National University and grant no. 14-2017-007 from the SNUBH Research Fund. The funding source had no role in the study design, data collection, data analysis, data interpretation, or writing of the manuscript.


The authors have no potential conflicts of interest to disclose.


Author Contributions

Conceptualization: all authors. Methodology: all authors. Validation: Euitae Kim. Formal analysis: Royun Park. Investigation: Euitae Kim, Seoyoung Kim. Data curation: Euitae Kim, Royun Park. Writing—original draft preparation: Royun Park. Writing—review & editing: Euitae Kim, Seoyoung Kim.

Figure 1.
Schematic diagram of assessment schedule summarized from retrospectively obtained clinical data. The midline and error bars indicate mean and standard deviation of days after the initiation of clozapine treatment that each assessment was made.
Figure 2.
Scatter plots of the Δclozapine/NDMC ratio and Δstandardized T-scores for performance in cognitive domains. The Pearson correlation coefficient r and p-value of each cognitive domain are shown in each panel. The values of 4 patients that had initial assessments before clozapine initiation were not included in the analysis. Δ=(assessment at follow up - assessment at baseline)/(assessment at baseline)×100, Δclozapine/NDMC ratio=(clozapine/NDMC ratio at follow-up - clozapine/NDMC ratio at baseline)/(clozapine/NDMC ratio at baseline)×100. NDMC: N-desmethylclozapine.
Table 1.
Demographic, pharmacologic, and clinical characteristics of 15 patients with schizophrenia who received clozapine treatment
Parameters Initial assessment
Follow-up assessment
ta Zb p-value
Mean SD Mean SD
Sex (M/F) 5/10
Age (y) 34.13 13.31
Education (y) 13.47 2.75
Clozapine dosage (mg/d) 135.00 122.32 199.17 86.42 -1.850 0.086
Clozapine concentration (nmol/L) 260.62 235.42 348.91 225.21 -0.961 0.353
NDMC concentration (nmol/L) 133.86 139.70 222.68 141.54 -1.988 0.047*
Clozapine/NDMC ratio 1.68c 1.45c 1.74 0.70 -0.180 0.860
Positive and Negative Syndrome Scale
 Total score 77.92 19.70 75.27 18.27 -0.035 0.972
 Positive score 17.38 6.07 15.00 4.63 1.156 0.270
 Negative score 20.69 5.43 20.00 5.48 0.047 0.963
 General score 39.85 10.44 40.27 10.41 -0.236 0.814

a t-value of paired t-test,

b Z-value of Wilcoxon signed-rank test,

c The values of 4 patients that had initial assessments before clozapine initiation were not included in the analysis.

* p<0.05.

NDMC: N-desmethylclozapine

Table 2.
Standardized T-scores of cognitive tests at initial and follow-up assessments
MATRICS consensus cognitive battery Initial assessment
Follow-up assessment
t p-value
Mean SD Mean SD
Processing speed 27.87 14.35 34.00 18.13 -2.229 0.043*
 Trail Making Test, part A (TMT) 33.47 12.95 39.87 20.72 -1.605 0.131
 Symbol coding task (BACS) 31.27 11.28 34.67 14.23 -1.493 0.158
 Category fluency (Fluency) 36.53 8.94 39.40 12.06 -1.405 0.182
Attention/vigilance 31.27 13.38 38.13 14.47 -3.031 0.009**
 Continuous Performance Test, Identical Pairs (CPT-IP) 31.27 13.38 38.13 14.47 -3.031 0.009**
Working memory 31.87 8.91 35.33 10.89 -1.519 0.151
 Spatial Span test (SS) 42.33 7.90 45.07 12.25 -0.922 0.372
 Letter-Number Span test (LNS) 27.20 8.26 30.87 7.97 -2.359 0.033*
Verbal learning 32.73 8.47 32.20 6.31 0.372 0.715
 Hopkins Verbal Learning Test-Revised (HVLT-R) 32.73 8.47 32.20 6.31 0.372 0.715
Visual learning 34.27 15.25 36.53 10.75 -0.801 0.437
 Brief Visuospatial Memory Test-Revised (BVMT-R) 34.27 15.25 36.53 10.75 -0.801 0.437
Reasoning and problem solving 38.13 11.07 40.67 8.47 -0.994 0.337
 Mazes test (Mazes) 38.13 11.07 40.67 8.47 -0.994 0.337
Social cognition 31.53 7.69 30.86 12.97 0.294 0.773
 Managing Emotions test (ME) 31.53 7.69 30.86 12.97 0.294 0.773
Overall composite score 21.6 21.60 28.64 12.25 -2.275 0.040*

* p<0.05,

** p<0.01.

MATRICS: Measurement and Treatment Research to Improve Cognition in Schizophrenia, BACS: Brief Assessment of Cognition in Schizophrenia

Table 3.
Results of stepwise multiple regression analyses with delta values of all cognitive domains and their corresponding tests as dependent variables
Model B SE B β p-value
ΔAttention/vigilance (R2=0.457, p=0.032*)
 (constant) 27.920 16.555 0.130
 ΔClozapine/NDMC ratio -1.083 0.418 -0.676 0.032*
ΔWorking memory (R2=0.483, p=0.026*)
 (constant) 8.744 9.847 0.400
 ΔClozapine concentration -0.384 0.141 -0.695 0.026*
ΔSocial cognition (R2=0.769, p=0.001**)
 (constant) -22.206 5.643 0.004**
 ΔClozapine concentration -0.416 0.081 -0.877 0.001**

The values of 4 patients that had initial assessments before clozapine initiation were not included in the analysis. Δ=(assessment at follow up - assessment at baseline)/(assessment at baseline)×100, Δclozapine/NDMC ratio=(clozapine/NDMC ratio at follow-up-clozapine/NDMC ratio at baseline)/(clozapine/NDMC ratio at baseline)×100.

* p<0.05,

** p<0.01.

B: parameter estimate, SE B: standard error of B, β: standardized B, NDMC: N-desmethylclozapine


1. Owen MJ, Sawa A Mortensen PB. Schizophrenia. Lancet 2016;388:86-97.
crossref pmid pmc
2. Joyce EM, Roiser JP. Cognitive heterogeneity in schizophrenia. Curr Opin Psychiatry 2007;20:268-272.
crossref pmid pmc
3. Danion JM, Huron C, Vidailhet P, Berna F. Functional mechanisms of episodic memory impairment in schizophrenia. Can J Psychiatry 2007;52:693-701.
crossref pmid
4. Galderisi S, Rossi A, Rocca P, Bertolino A, Mucci A, Bucci P, et al. Pathways to functional outcome in subjects with schizophrenia living in the community and their unaffected first-degree relatives. Schizophr Res 2016;175:154-160.
crossref pmid
5. Citrome L. Unmet needs in the treatment of schizophrenia: new targets to help different symptom domains. J Clin Psychiatry 2014;75(Suppl 1):21-26.
crossref pmid
6. Nielsen RE, Levander S, Kjaersdam Telleus G, Jensen SO, Ostergaard Christensen T, Leucht S. Second-generation antipsychotic effect on cognition in patients with schizophrenia--a meta-analysis of randomized clinical trials. Acta Psychiatr Scand 2015;131:185-196.
crossref pmid
7. Davis JM, Chen N, Glick ID. A meta-analysis of the efficacy of secondgeneration antipsychotics. Arch Gen Psychiatry 2003;60:553-564.
crossref pmid
8. Leucht S, Cipriani A, Spineli L, Mavridis D, Orey D, Richter F, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet 2013;382:951-962.
crossref pmid
9. Shirazi-Southall S, Rodriguez DE, Nomikos GG. Effects of typical and atypical antipsychotics and receptor selective compounds on acetylcholine efflux in the hippocampus of the rat. Neuropsychopharmacology 2002;26:583-594.
crossref pmid
10. Nucifora FC Jr, Mihaljevic M, Lee BJ, Sawa A. Clozapine as a Model for Antipsychotic Development. Neurotherapeutics 2017;14:750-761.
crossref pmid pmc
11. Chakos M, Lieberman J, Hoffman E, Bradford D, Sheitman B. Effectiveness of second-generation antipsychotics in patients with treatmentresistant schizophrenia: a review and meta-analysis of randomized trials. Am J Psychiatry 2001;158:518-526.
crossref pmid
12. Buchanan RW, Holstein C, Breier A. The comparative efficacy and long-term effect of clozapine treatment on neuropsychological test performance. Biol Psychiatry 1994;36:717-725.
crossref pmid
13. Lameh J, Burstein ES, Taylor E, Weiner DM, Vanover KE, Bonhaus DW. Pharmacology of N-desmethylclozapine. Pharmacol Ther 2007;115:223-231.
14. Weiner DM, Meltzer HY, Veinbergs I, Donohue EM, Spalding TA, Smith TT, et al. The role of M1 muscarinic receptor agonism of N-desmethylclozapine in the unique clinical effects of clozapine. Psychopharmacology (Berl) 2004;177:207-216.
crossref pmid
15. Snyder S, Greenberg D, Yamamura HI. Antischizophrenic drugs and brain cholinergic receptors. Affinity for muscarinic sites predicts extrapyramidal effects. Arch Gen Psychiatry 1974;31:58-61.
crossref pmid
16. Chew ML, Mulsant BH, Pollock BG, Lehman ME, Greenspan A, Mahmoud RA, et al. Anticholinergic activity of 107 medications commonly used by older adults. J Am Geriatr Soc 2008;56:1333-1341.
crossref pmid
17. Davies MA, Compton-Toth BA, Hufeisen SJ, Meltzer HY, Roth BL. The highly efficacious actions of N-desmethylclozapine at muscarinic receptors are unique and not a common property of either typical or atypical antipsychotic drugs: is M1 agonism a pre-requisite for mimicking clozapine’s actions? Psychopharmacology (Berl) 2005;178:451-460.
crossref pmid
18. Sur C, Mallorga PJ, Wittmann M, Jacobson MA, Pascarella D, Williams JB, et al. N-desmethylclozapine, an allosteric agonist at muscarinic 1 receptor, potentiates N-methyl-D-aspartate receptor activity. Proc Natl Acad Sci U S A 2003;100:13674-13679.
crossref pmid pmc
19. Bondesson U, Lindstrom LH. Determination of clozapine and its Ndemethylated metabolite in plasma by use of gas chromatography-mass spectrometry with single ion detection. Psychopharmacology (Berl) 1988;95:472-475.
20. Rajji TK, Mulsant BH, Davies S, Kalache SM, Tsoutsoulas C, Pollock BG, et al. Prediction of working memory performance in schizophrenia by plasma ratio of clozapine to N-desmethylclozapine. Am J Psychiatry 2015;172:579-585.
crossref pmid
21. McArdle PA, De Mel V, DeMonte V, Winckel K, Gore-Jones V, Foley S, et al. An investigation into the relationship between clozapine treatment and cognitive performance in patients with treatment resistant schizophrenia. Schizophr Res 2019;206:450-451.
crossref pmid
22. Molins C, Carceller-Sindreu M, Navarro H, Carmona C, Pineiro M, Martinez E, et al. Plasma ratio of clozapine to N-desmethylclozapine can predict cognitive performance in treatment-resistant psychotic patients. Psychiatry Res 2017;258:153-157.
crossref pmid
23. Rajji TK, Uchida H, Ismail Z, Ng W, Mamo DC, Remington G, et al. Clozapine and global cognition in schizophrenia. J Clin Psychopharmacol 2010;30:431-436.
crossref pmid
24. Dal Santo F, Jarratt-Barnham I, González-Blanco L, García-Portilla MP, Bobes J Fernández-Egea E. Longitudinal effects of clozapine concentration and clozapine to N-desmethylclozapine ratio on cognition: a mediation model. Eur Neuropsychopharmacol 2020;33:158-163.
crossref pmid
25. Aravagiri M, Marder SR. Simultaneous determination of clozapine and its N-desmethyl and N-oxide metabolites in plasma by liquid chromatography/electrospray tandem mass spectrometry and its application to plasma level monitoring in schizophrenic patients. J Pharm Biomed Anal 2001;26:301-311.
26. Kay SR, Opler LA, Lindenmayer JP. Reliability and validity of the positive and negative syndrome scale for schizophrenics. Psychiatry Res 1988;23:99-110.
crossref pmid
27. Kern RS, Gold JM, Dickinson D, Green MF, Nuechterlein KH, Baade LE, et al. The MCCB impairment profile for schizophrenia outpatients: results from the MATRICS psychometric and standardization study. Schizophr Res 2011;126:124-131.
crossref pmid
28. Georgiades A, Davis VG, Atkins AS, Khan A, Walker TW, Loebel A, et al. Psychometric characteristics of the MATRICS Consensus Cognitive Battery in a large pooled cohort of stable schizophrenia patients. Schizophr Res 2017;190:172-179.
crossref pmid
29. Nuechterlein KH, Green MF, Kern RS, Baade LE, Barch DM, Cohen JD, et al. The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity. Am J Psychiatry 2008;165:203-213.
30. Hasselmo ME, Sarter M. Modes and models of forebrain cholinergic neuromodulation of cognition. Neuropsychopharmacology 2011;36:52-73.
crossref pmid
31. Couchman L, Morgan PE, Spencer EP, Flanagan RJ. Plasma clozapine, norclozapine, and the clozapine:norclozapine ratio in relation to prescribed dose and other factors: data from a therapeutic drug monitoring service, 1993-2007. Ther Drug Monit 2010;32:438-447.
crossref pmid
32. Chetty M, Murray M. CYP-mediated clozapine interactions: how predictable are they? Curr Drug Metab 2007;8:307-313.
crossref pmid
33. Urichuk L, Prior TI, Dursun S, Baker G. Metabolism of atypical antipsychotics: involvement of cytochrome p450 enzymes and relevance for drug-drug interactions. Curr Drug Metab 2008;9:410-418.
crossref pmid
34. Cheng YF, Lundberg T, Bondesson U, Lindström L, Gabrielsson J. Clinical pharmacokinetics of clozapine in chronic schizophrenic patients. Eur J Clin Pharmacol 1988;34:445-449.
crossref pmid
35. Schoretsanitis G, Kane JM, Ruan CJ, Spina E, Hiemke C, de Leon J. A comprehensive review of the clinical utility of and a combined analysis of the clozapine/norclozapine ratio in therapeutic drug monitoring for adult patients. Expert Rev Clin Pharmacol 2019;12:603-621.
crossref pmid
36. Rostami-Hodjegan A, Amin AM, Spencer EP, Lennard MS, Tucker GT, Flanagan RJ. Influence of dose, cigarette smoking, age, sex, and metabolic activity on plasma clozapine concentrations: a predictive model and nomograms to aid clozapine dose adjustment and to assess compliance in individual patients. J Clin Psychopharmacol 2004;24:70-78.
crossref pmid
37. Jacob A, Zahr N, Hulot JS, Boussouar S, Vilain J, Lafont-Rapnouil S, et al. Therapeutic drug monitoring of clozapine in a hemodialysed smoking patient with schizophrenia. Ther Drug Monit 2009;31:281-282.
crossref pmid
38. Rajkumar AP, Poonkuzhali B, Kuruvilla A, Jacob M, Jacob KS. Clinical predictors of serum clozapine levels in patients with treatment-resistant schizophrenia. Int Clin Psychopharmacol 2013;28:50-56.
crossref pmid
Facebook Twitter Linked In Google+
METRICS Graph View
  • 0 Crossref
  •   Scopus
  • 1,066 View
  • 64 Download


Browse all articles >

Editorial Office
#522, 27, Seochojungang-ro 24-gil, Seocho-gu, Seoul 06601, Korea
Tel: +82-2-537-6171    Fax: +82-2-537-6174    E-mail:                

Copyright © 2021 by Korean Neuropsychiatric Association.

Developed in M2PI

Close layer
prev next